Antiplatelet aggregation assay

Intraperitoneal administration of coptisine at dosages of 0.5, 1, and 5 mg/kg/day to original-type anti-GBM-induced nephritic rats was shown to be effective in the inhibition of urinary protein excretion, elevation of serum cholesterol, and creatinine contents, as well glomerular histopathological changes. The alkaloid inhibited platelet aggregation in both in vitro and in vivo assays. These results suggest that the antinephritic effect of coptisine may be due partly to antiplatelet action and improved renal hemodynamics, via the alteration of prostanoid synthesis [223]. 

---